GLP-1 drugs for weight loss have become popular because they’re very effective. But there are some significant risks that may not be readily apparent to patients — most notably the potential for muscle loss. GLP-1s helps regulate blood sugar levels, appetite and satiety. This class of drugs enhances insulin secretion, suppresses glucagon release, slows gastric…
A study recently published in the Lancet paints a grim picture of the obesity epidemic in the United States: nearly three quarters of adults in the U.S. are classified as overweight or obese. The health risks associated with this are significant and include diabetes, high blood pressure, heart disease, and shortened lifespan. As a company…
NORTHBROOK, Ill., Nov. 12, 2024 /PRNewswire/ The Journal of Clinical Investigation (JCI) publishes results of a Melanocortin-4 receptor antagonist, TCMCBO7 Endevica Bio’s experimental peptide to prevent weight loss associated with cachexia improved the appetite and preserved lean mass and fat mass in rodent models of cancer chemotherapy, according to data from a preclinical study published today in…
To successfully treat cachexia, a severe wasting condition characterized by unintentional weight loss, we can’t wait until patients have lost significant amounts of muscle mass. Once that happens, it becomes extremely difficult to regain it. We think the key is to prevent the condition as soon as a healthcare provider determines a patient has a…
Endevica Bio’s experimental drug to treat obesity has its roots in my research seeking to do the reverse: help people gain weight. During my medical fellowship more than two decades ago, I worked in a lab where everyone was studying obesity – a disease that affects more than 40% of Americans. But my interest was…
Authors: Xinxia Zhu, Russell Potterfield, Kenneth A. Gruber, Emma Zhang, Samuel D. Newton, Mason A. Norgard, Peter R. Levasseur, Peng Bai, Xu Chen, Qingyang Gu, Aaron J. Grossberg, and Daniel L. Marks Abstract: Cancer patients undergoing chemotherapy often experience anorexia and weight loss that substantially deteriorates overall health, reduces treatment tolerance and quality of life, and worsens oncologic outcomes. There are currently few effective therapeutic options…
Cachexia, a severe weight loss and muscle wasting syndrome, exacts a heavy toll on patients. But there’s another group that suffers from cachexia in silence: caregivers. Cachexia patients often lose their ability to take care of themselves, requiring help with day-to-day activities. That imposes a significant burden on those who provide care, often family members…
As scientists research treatments for cachexia, a wasting syndrome characterized by significant involuntary weight loss and muscle atrophy, there is a growing recognition that medications for this condition need to target the brain. There is currently no drug on the market in the U.S. that effectively treats cachexia, which is typically associated with cancer and…
Peptides – short chains of amino acids, the building blocks of proteins — are emerging as a cornerstone of innovation and therapeutic potential. They are smaller than proteins and are more easily absorbed into the body. Compared to small molecules, peptides can better target diseases and do so with fewer side effects. There is a…
Most people haven’t heard of a wasting syndrome called cachexia – even though it will be a factor in roughly a third of the 600,000 cancer deaths this year in the U.S. If you haven’t heard of cachexia, there’s a reason. There aren’t high profile education campaigns. And doctors don’t spend much time talking about…